Surgery Websites
Thoracic Oncology Program »  Meet the Team »  Medical Oncologists »  Thierry Marie Jahan, M.D.

Thierry Marie Jahan, M.D.

Professor of Medicine
Chair, Data and Safety Monitoring Committee
Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology
UCSF Helen Diller Family Comprehensive Cancer Center

Contact Information

(415) 885-3882  Appointments
(415) 353-7151  Clinic Fax
Thierry.Jahan@ucsf.edu
Open Popup
  • 1977-1980, Université de Paris V-René Descartes, Paris France
  • 1980-1983, Columbia College, NYC, NY, BA, Psychology
  • 1983-1987, George Washington University School of Medicine, Washington, DC, M.D.
  • 1987-1988, Cedars Sinai Med. Ctr/UCLA, Los Angeles, CA, Internship, Internal Medicine
  • 1988-1990, Cedars Sinai Med. Ctr/UCLA, Los Angeles, CA, Resident, Internal Medicine
  • 1990-1991, Cedars Sinai Medical Ctr/UCLA, Los Angeles, CA, Kennamer Fellow in Internal Medicine
  • 1991-1994, UCSF, San Francisco, CA, Hematology/Oncology Fellow
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Hematology
  • American Board of Internal Medicine, Medical Oncology
  • Department of Medicine, Division of Hematology Oncology, Thoracic Oncology Program
  • Member, UCSF Helen Diller Family Comprehensive Cancer Center
  • Novel agents in mesothelioma non-small cell lung cancer
  • French, Russian, Spanish

Thierry M. Jahan, M.D. is a renowned medical oncologist who specializes in the treatment of thoracic malignancies such as lung cancer and mesothelioma, and soft tissue sarcomas. Dr. Jahan received his M.D. from George Washington University, thereafter completing his residency and internal medicine residency at Cedars Sinai Medical Center in Los Angeles. He later was a clinical fellows in hematology and oncology at UCSF, eventually joining the UCSF faculty. Dr. Jahan co-founded the Thoracic Oncology Program with David Jablons, M.D. 

In addition to his keen clinical insight, Dr. Jahan is known by patients, their families and fellow clinicians for his sense of empathy and compassion. His steadfast commitment to eliminating the scourge of lung cancer is evidenced by the pins and ribbons adorning his white coat, a clear message of hope to patients.

In 2016, Dr. Jahan was inducted into the Council of Master Clinicians by the UCSF Department of Medicine, a select group of outstanding physicians with exceptional knowledge, superior teaching and communication skills, and the ability to provide compassionate, appropriate, effective, and high-quality patient care. 

Dr. Jahan has been the recipient of numerous awards including the Medical House Staff Outstanding Teacher Award and Friend of the Palliative Care Service Award. He is also a member of numerous professional organizations, including the American College of Physicians, American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC) and the Association of Northern California Oncologists.

Dr. Jahan has authored or co-authored numerous peer-reviewed articles, book chapters and research abstracts and lectured nationally and internationally on lung cancer and mesothelioma. Numerous major media outlets including The San Francisco Chronicle, Time Magazine and KPIX San Francisco have sought out his opinions and observations on treatments and advances in lung cancer.

Dr. Jahan is Principal Investigator on numerous thoracic oncology clinical trials. He has a particular interest in testing target therapies in non-small cell lung cancer malignant mesothelioma as either single agents or in combination with chemotherapy and/or radiation.

Data provided by UCSF Profiles, powered by CTSI
MOST RECENT PUBLICATIONS FROM A TOTAL OF 62
Data provided by UCSF Profiles, powered by CTSI
  1. Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, Coussens LM, Brockstedt DG. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2019 10 01; 25(19):5787-5798. View in PubMed
  2. Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, Gubens MA, Jahan TM, Jones KD, Kim IJ, He B, Jablons DM, Mann MJ. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging. J Thorac Oncol. 2019 07; 14(7):1223-1232. View in PubMed
  3. Utne I, Løyland B, Grov EK, Rasmussen HL, Torstveit AH, Cooper BA, Mastick J, Mazor M, Wong M, Paul SM, Conley YP, Jahan T, Ritchie C, Levine JD, Miaskowski C. Distinct attentional function profiles in older adults receiving cancer chemotherapy. Eur J Oncol Nurs. 2018 Oct; 36:32-39. View in PubMed
  4. Kindler HL, Ismaila N, Armato SG, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, Rusch V, Sterman D, Thomas A, Hassan R. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 05 01; 36(13):1343-1373. View in PubMed
  5. Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 01; 19(1):58-64. View in PubMed
  6. View All Publications

 

Site Directory
    X